Top 10 Biotechnology Companies - SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline

Find Industry reports, Company profiles
ReportLinker and Market Statistics

>> Get this Report Now by email!

Top 10 Biotechnology Companies - SWOT Analysis, Competitive
Benchmarking, Financial Analysis and R&D Pipeline
Published on February 2010

Report Summary

Top 10 Biotechnology Companies - SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline

Summary

GBI Research, the leading business intelligence provider, has released its latest research, 'Top 10 Biotechnology Companies - SWOT
Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline', which provides an insight into the global biotechnology
industry and analyzes the competitive positioning of the top 10 companies in the industry. This pharmaceutical and healthcare report
estimates the market size of the global biotechnology industry and its future prospects. It benchmarks the leading companies in the
biotechnology industry on selected parameters to analyze their competitive positioning in the market. The report analyzes the future
landscape of the biotechnology industry by forecasting the revenues of leading companies to 2012. For each company the report
analyzes the financial strength, product portfolio, pipeline strength and therapeutic focus of its R&D activities. It critically examines the
strengths and weaknesses of individual companies and the opportunities and threats facing them.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house
analysis by GBI Research's team of industry experts.

Scope

The report analyses the competitive landscape of the biotechnology industry, R&D strategies and pipeline of the top 10 players, and
strengths, weaknesses, opportunities and threats facing these companies. Its scope includes
- Market size of the global biotechnology industry and coverage of the changing competitive landscape from 2008 to 2012.
- Review of key industry drivers and restraints which are likely to impact the global biotechnology industry in the future.
- Analysis of the competitive positioning of the top 10 biotechnology companies globally.
- Analysis of pipeline products in the global biotech market by therapy area like cancer, infectious diseases, respiratory disorders,
autoimmune disorders, and product classes.
- Financial analysis including annual revenues of top 10 companies from 2004 to 2008, with forecasts to 2012.
- SWOT analysis, DuPont analysis and financial benchmarking of the top 10 biotech companies.
- Analysis of the therapeutic focus, marketed products and product pipeline of top 10 biotech companies.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop a clear knowledge and understanding of the competitive landscape and how this will change in the coming years.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive
advantage.
- Effectively plan your M&A and partnership strategies by identifying companies with the most promising pipeline.
- Make more informed business decisions from the insightful and in-depth analysis of the key strategies to be followed by competitors.

- Effectively plan your investment strategies by identifying companies with maximum investment potential.

Top 10 Biotechnology Companies - SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline Page 1/14


- Identify key winners and losers and who is best positioned to take advantage of the emerging market opportunities.

Table of Content

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 9
1.2 List of Figures 12
2 Introduction 15
2.1 GBI Research Report Guidance 16
3 Global Biotechnology Industry ' Market Characterization 17
3.1 Global Biotechnology Industry ' Market Size 17
3.2 Top 10 Companies ' Market Forecast 18
3.3 Therapeutic Focus of the Biotechnology Industry 20
3.4 Global Biotechnology Industry ' Growth Drivers and Restraints 22
3.4.1 Growth Drivers 22
3.4.2 Restraints 23
4 Top 10 Biotechnology Companies ' Competitive Landscape 24
4.1 Competitive Landscape Framework 24
4.2 Financial Benchmarking 25
4.2.1 Earnings per Share 26
4.2.2 Net Profit Margin 26
4.2.3 Current Ratio 27
4.2.4 Debt to Equity ratio 27
4.2.5 Asset Turnover Ratio 28
4.3 R&D Productivity Framework 28
5 Global Biotechnology Industry ' Strategic Consolidations 30
5.1 Pharma Biotech Space ' Deals Analysis (2008) 30
5.2 Increasing Interest of Big Pharma Companies in the Biotech Industry 31
6 Top 10 Biotechnology Companies ' Amgen 33
6.1 Company Overview 33
6.1.1 Introduction 33
6.1.2 Business Description 33
6.2 Strategic Positioning 34
6.2.1 SWOT Analysis 34
6.3 Financial Analysis 36
6.3.1 Revenue Analysis and Forecasts 36
6.3.2 Ratio Analysis 39
6.3.3 DuPont Analysis 43
6.4 Marketed Products 44
6.4.1 Key Marketed Products 44
6.5 R&D Strategies 45
6.5.1 Therapeutic Focus 45
6.5.2 R&D Productivity 46
6.6 Product Pipeline 47
6.6.1 Overview 47
6.6.2 Key Pipeline Products 48
6.7 Licensing Agreements 49



6.7.1 Overview 49
7 Top 10 Biotechnology Companies ' Genentech (Roche) 50
7.6.1 Overview 62
7.7.1 Overview 64
8 Top 10 Biotechnology Companies ' Gilead Sciences 66
8.6.1 Overview 78
8.7.1 Overview 79
9 Top 10 Biotechnology Companies ' UCB Pharma 80



9.6.1 Overview 92
9.7.1 Overview 93
10 Top 10 Biotechnology Companies ' Genzyme 94
10.6.1 Overview 106
10.7.1 Overview 107
11 Top 10 Biotechnology Companies ' Biogen Idec 109
11.6.1 Overview 121



11.7.1 Overview 122
12 Top 10 Biotechnology Companies ' CSL Limited 123
12.6.1 Overview 135
12.7.1 Overview 136
13 Top 10 Biotechnology Companies ' Celgene 137
13.6.1 Overview 148
13.7.1 Overview 149
14 Top 10 Biotechnology Companies ' Cephalon 150



14.6.1 Overview 161
14.7.1 Overview 162
15 Top 10 Biotechnology Companies ' Actelion 163
15.6.1 Overview 174
15.7.1 Overview 175
16 Top 10 Biotechnology Companies ' Appendix 176
16.1 Market Definitions 176
16.2 Abbreviations 178
16.3 Research Methodology 178
16.3.1 Coverage 179
16.3.2 Secondary Research 179
16.3.3 Primary Research 180
16.3.4 Expert Panel Validation 180
16.4 Contact Us 180
16.5 Disclaimer 180
16.6 Sources 181

1.1 List of Tables
Table 1: Top 10 Biotechnology Companies, Global, Annual Revenues, ($m), 2008 17
Table 2: Global, Top 25 Biologic Drugs by Annual Sales. 2008 18
Table 3: Top 10 Biotechnology Companies, Global, Revenue Forecast, ($m), 2008-2012 19
Table 4: Top 10 Biotechnology Companies, Global, Company Rankings, 2008-2012 20
Table 5: Top 10 Biotechnology Companies, Global, Rankings by Strength of Marketed and Pipeline Products, 2008 25
Table 6: Top 10 Biotechnology Companies, Global, Earnings per Share, ($), 2008 26



Table 7: Top 10 Biotechnology Companies, Global, Net Profit Margin, (%), 2008 26
Table 8: Top 10 Biotechnology Companies, Global, Current Ratio, 2008 27
Table 9: Top 10 Biotechnology Companies, Global, Debt to Equity Ratio, 2008 27
Table 10: Top 10 Biotechnology Companies, Global, Asset Turnover Ratio, 2008 28
Table 11: Top 10 Biotechnology Companies, Global, Rankings by Strength of Pipeline Products in Each Therapy Area (1), 2008 29
Table 12: Top 10 Biotechnology Companies, Global, Rankings by Strength of Pipeline Products in Each Therapy Area (2), 2008 29
Table 13: Biotechnology Industry, Global, Key M&A Deals in 2008 30
Table 14: Global, Value of Drugs Going Off-Patent by Therapeutic Area, ($m), 2009'2014 31
Table 15: Amgen Inc., Historical Revenue, ($m), 2004-2008 37
Table 16: Amgen Inc., Revenue Forecast, ($m), 2008-2012 37
Table 17: Amgen Inc., Net Income and R&D Expense, ($m), 2004-2008 38
Table 18: Equity Ratios for Amgen Inc., ($), 2004-2008 39
Table 19: Profitability Ratios for Amgen Inc., (%), 2004-2008 40
Table 20: Liquidity Ratios for Amgen Inc., 2004-2008 41
Table 21: Leverage Ratios for Amgen Inc., 2004-2008 42
Table 22: Efficiency Ratios for Amgen Inc., 2004-2008 42
Table 23: Expenditure on R&D for Amgen Inc., ($m), 2004-2008 46
Table 24: Phase-wise Analysis of Amgen R&D Pipeline, 2009 47
Table 25: Amgen Inc., Licensing Agreements for Drugs, 2008-July 2009 49
Table 26: Genentech, Historical Revenue, ($m), 2004-2008 53
Table 27: Genentech, Revenue Forecast, ($m), 2008-2012 53
Table 28: Genentech, Net Income and R&D Expense, ($m), 2004-2008 54
Table 29: Equity Ratios for Genentech, ($), 2004-2008 55
Table 30: Profitability Ratios for Genentech, (%), 2004-2008 56
Table 31: Liquidity Ratios for Genentech, 2004-2008 57
Table 32: Leverage Ratios for Genentech, 2004-2008 58
Table 33: Efficiency Ratios for Genentech, 2004-2008 59
Table 34: Expenditure on R&D for Genentech, ($m), 2004-2008 62
Table 35: Phase-wise Analysis of Genentech R&D Pipeline, 2009 62
Table 36: Genentech, Licensing Agreements for Drugs, 2008-July 2009 65
Table 37: Gilead, Historical Revenue, ($m), 2004-2008 69
Table 38: Gilead, Revenue Forecast, ($m), 2008-2012 69
Table 39: Gilead, Net Income and R&D Expense, ($m), 2004-2008 70
Table 40: Equity Ratios for Gilead, ($), 2004-2008 71
Table 41: Profitability Ratios for Gilead, (%), 2004-2008 72
Table 42: Liquidity Ratios for Gilead, 2004-2008 73
Table 43: Leverage Ratios for Gilead, 2004-2008 74
Table 44: Efficiency Ratios for Gilead, 2004-2008 74
Table 45: Expenditure on R&D by Gilead, ($m), 2004-2008 77
Table 46: Phase-wise Analysis of Gilead R&D Pipeline, 2009 78
Table 47: Gilead, Licensing Agreements for Drugs, 2008-July 2009 79
Table 48: UCB Pharma, Historical Revenue, ($m), 2004-2008 83
Table 49: UCB Pharma, Revenue Forecast, ($m), 2008-2012 83
Table 50: UCB Pharma, Net Income and R&D Expense, ($m), 2004-2008 84
Table 51: Equity Ratios for UCB Pharma, ($), 2004-2008 85
Table 52: Profitability Ratios for UCB Pharma, (%), 2004-2008 86
Table 53: Liquidity Ratios for UCB Pharma, 2004-2008 87
Table 54: Leverage Ratios for UCB Pharma, 2004-2008 88
Table 55: Efficiency Ratios for UCB Pharma, 2004-2008 88
Table 56: Expenditure on R&D by UCB Pharma, ($m), 2004-2008 91



Table 57: Phase-wise Analysis of UCB Pharma R&D Pipeline, 2009 92
Table 58: UCB Pharma, Licensing Agreements for Drugs, 2008-July 2009 93
Table 59: Genzyme, Historical Revenue, ($m), 2004-2008 97
Table 60: Genzyme, Revenue Forecast, ($m), 2008-2012 98
Table 61: Genzyme, Net Income and R&D Expense, ($m), 2004-2008 98
Table 62: Equity Ratios for Genzyme, ($), 2004-2008 99
Table 63: Profitability Ratios for Genzyme, (%), 2004-2008 100
Table 64: Liquidity Ratios for Genzyme, 2004-2008 101
Table 65: Leverage Ratios for Genzyme, 2004-2008 102
Table 66: Efficiency Ratios for Genzyme, 2004-2008 102
Table 67: Expenditure on R&D by Genzyme, ($m), 2004-2008 105
Table 68: Phase-wise Analysis of Genzyme R&D Pipeline, 2009 106
Table 69: Genzyme, Licensing Agreements for Drugs, 2008-July 2009 107
Table 70: Biogen Idec, Historical Revenue, ($m), 2004-2008 112
Table 71: Biogen Idec, Revenue Forecast, ($m), 2008-2012 112
Table 72: Biogen Idec, Net Income and R&D Expense, ($m), 2004-2008 113
Table 73: Equity Ratios for Biogen Idec, ($), 2004-2008 114
Table 74: Profitability Ratios for Biogen Idec, (%), 2004-2008 115
Table 75: Liquidity Ratios for Biogen Idec, 2004-2008 116
Table 76: Leverage Ratios for Biogen Idec, 2004-2008 117
Table 77: Efficiency Ratios for Biogen Idec, 2004-2008 117
Table 78: Expenditure on R&D for Biogen Idec, ($m), 2004-2008 120
Table 79: Phase-wise Analysis of Biogen Idec R&D Pipeline, 2009 121
Table 80: Biogen Idec, Licensing Agreements for Drugs, 2008-July 2009 122
Table 81: CSL Limited, Historical Revenue, ($m), 2005-2009 126
Table 82: CSL Limited, Revenue Forecast, ($m), 2009-2013 126
Table 83: CSL Limited, Net Income and R&D Expense, ($m), 2005-2009 127
Table 84: Equity Ratios for CSL Limited, ($), 2005-2009 128
Table 85: Profitability Ratios for CSL Limited, (%), 2005-2009 129
Table 86: Liquidity Ratios for CSL Limited, 2005-2009 130
Table 87: Leverage Ratios for CSL Limited, 2005-2009 131
Table 88: Efficiency Ratios for CSL Limited, 2005-2009 131
Table 89: Expenditure on R&D by CSL Limited, ($m), 2005-2009 134
Table 90: Phase-wise Analysis of CSL Limited R&D Pipeline, 2009 135
Table 91: CSL Limited, Licensing Agreements for Drugs, 2008-July 2009 136
Table 92: Celgene, Historical Revenue, ($m), 2004-2008 140
Table 93: Celgene, Revenue Forecast, ($m), 2008-2012 140
Table 94: Celgene, Net Income and R&D Expense, ($m), 2004-2008 141
Table 95: Equity Ratios for Celgene, ($), 2004-2008 142
Table 96: Profitability Ratios for Celgene, (%), 2004-2008 143
Table 97: Liquidity Ratios for Celgene, 2004-2008 143
Table 98: Leverage Ratios for Celgene, 2004-2008 144
Table 99: Efficiency Ratios for Celgene, 2004-2008 144
Table 100: Expenditure on R&D by Celgene, ($m), 2004-2008 147
Table 101: Phase-wise Analysis of Celgene R&D Pipeline, 2009 148
Table 102: Celgene, Licensing Agreements for Drugs, 2008-July 2009 149
Table 103: Cephalon, Historical Revenue, ($m), 2004-2008 153
Table 104: Cephalon, Revenue Forecast, ($m), 2008-2012 153
Table 105: Cephalon, Net Income and R&D Expense, ($m), 2004-2008 154
Table 106: Equity Ratios for Cephalon, ($), 2004-2008 155



Table 107: Profitability Ratios for Cephalon, (%), 2004-2008 156
Table 108: Liquidity Ratios for Cephalon, 2004-2008 156
Table 109: Leverage Ratios for Cephalon, 2004-2008 157
Table 110: Efficiency Ratios for Cephalon, 2004-2008 157
Table 111: Expenditure on R&D for Cephalon, ($m), 2004-2008 160
Table 112: Phase-wise Analysis of Cephalon R&D Pipeline, 2009 161
Table 113: Cephalon, Licensing Agreements for Drugs, 2008-July 2009 162
Table 114: Actelion, Historical Revenue, ($m), 2004-2008 166
Table 115: Actelion, Revenue Forecast, ($m), 2008-2012 166
Table 116: Actelion, Net Income and R&D Expense, ($m), 2004-2008 166
Table 117: Equity Ratios for Actelion, ($), 2004-2008 167
Table 118: Profitability Ratios for Actelion, (%), 2004-2008 168
Table 119: Liquidity Ratios for Actelion, 2004-2008 169
Table 120: Leverage Ratios for Actelion, 2004-2008 170
Table 121: Efficiency Ratios for Actelion, 2004-2008 170
Table 122: Expenditure on R&D by Actelion, ($m), 2004-2008 173
Table 123: Phase-wise Analysis of Actelion R&D Pipeline, 2009 174
Table 124: Actelion, Licensing Agreements for Drugs, 2008-July 2009 175

1.2 List of Figures
Figure 1: Top 10 Biotechnology Companies, Global, Annual Revenues, ($m), 2008 17
Figure 2: Top 10 Biotechnology Companies, Global, Revenue Forecast, ($m), 2008-2012 19
Figure 3: Global, Biotech Pipeline Drugs by Therapy Areas, (%), 2008 20
Figure 4: Global, Biotech Pipeline Drugs by Product Classes, 2008 21
Figure 5: Biotechnology Industry, Global, Growth Drivers and Restraints,2008 22
Figure 6: Top 10 Biotechnology Companies, Global, Competitive Positioning, 2008 24
Figure 7: Top 10 Biotechnology Companies, Global, Competitive Landscape Framework, 2008 25
Figure 8: Top 10 Biotechnology Companies, Global, R&D Productivity Framework, 2008 28
Figure 9: Global, Value of Drugs Going Off-Patent by Therapeutic Area, ($m), 2009'2014 31
Figure 10: SWOT Analysis of Amgen Inc. 34
Figure 11: Amgen Inc., Annual Revenue Forecasts, ($m), 2004-2012 37
Figure 12: Amgen Inc., Net Income and R&D Expense, ($m), 2004-2008 38
Figure 13: Amgen Inc., Earnings per Share, ($), 2004-2008 39
Figure 14: Amgen Inc., Net Profit Margin, (%), 2004-2008 40
Figure 15: Amgen Inc., Current Ratio, 2004-2008 41
Figure 16: Amgen Inc., Debt to Equity Ratio, 2004-2008 42
Figure 17: Amgen Inc., Return on Equity, (%), 2004-2008 43
Figure 18: DuPont Analysis for Amgen Inc., 2004-2008 43
Figure 19: Therapeutic Focus of Amgen R&D Pipeline, 2009 45
Figure 20: R&D Productivity for Amgen Inc., 2004-2008 46
Figure 21: Phase-wise Analysis of Amgen R&D Pipeline, 2009 47
Figure 22: SWOT Analysis of Genentech 51
Figure 23: Genentech, Annual Revenue Forecasts, ($m), 2004-2012 53
Figure 24: Genentech, Net Income and R&D Expense, ($m), 2004-2008 54
Figure 25: Genentech, Earnings per Share, ($), 2004-2008 55
Figure 26: Genentech, Net Profit Margin, (%), 2004-2008 56
Figure 27: Genentech, Current Ratio, 2004-2008 57
Figure 28: Genentech, Debt to Equity Ratio, 2004-2008 58
Figure 29: Genentech, Return on Equity, (%), 2004-2008 59
Figure 30: DuPont Analysis for Genentech, 2004-2008 60



Figure 31: Therapeutic Focus of Genentech R&D Pipeline, 2009 61
Figure 32: R&D Productivity for Genentech, 2004-2008 61
Figure 33: Phase-wise Analysis of Genentech R&D Pipeline, 2009 62
Figure 34: SWOT Analysis of Gilead 67
Figure 35: Gilead, Annual Revenue Forecasts, ($m), 2004-2012 69
Figure 36: Gilead, Net Income and R&D Expense, ($m), 2004-2008 70
Figure 37: Gilead, Earnings per Share, ($), 2004-2008 71
Figure 38: Gilead, Net Profit Margin, (%), 2004-2008 72
Figure 39: Gilead, Current Ratio, 2004-2008 73
Figure 40: Gilead, Debt to Equity Ratio, 2004-2008 74
Figure 41: Gilead, Return on Equity, (%), 2004-2008 75
Figure 42: DuPont Analysis for Gilead, 2004-2008 75
Figure 43: Therapeutic Focus of Gilead R&D Pipeline, 2009 76
Figure 44: R&D Productivity for Gilead, 2004-2008 77
Figure 45: Phase-wise Analysis of Gilead R&D Pipeline, 2009 78
Figure 46: SWOT Analysis of UCB Pharma 81
Figure 47: UCB Pharma, Annual Revenue Forecasts, ($m), 2004-2012 83
Figure 48: UCB Pharma, Net Income and R&D Expense, ($m), 2004-2008 84
Figure 49: UCB Pharma, Earnings per Share, ($), 2004-2008 85
Figure 50: UCB Pharma, Net Profit Margin, (%), 2004-2008 86
Figure 51: UCB Pharma, Current Ratio, 2004-2008 87
Figure 52: UCB Pharma, Debt to Equity Ratio, 2004-2008 88
Figure 53: UCB Pharma, Return on Equity, (%), 2004-2008 89
Figure 54: DuPont Analysis for UCB Pharma, 2004-2008 89
Figure 55: Therapeutic Focus of UCB Pharma R&D Pipeline, 2009 90
Figure 56: R&D Productivity for UCB Pharma, 2004-2008 91
Figure 57: Phase-wise Analysis of UCB Pharma R&D Pipeline, 2009 92
Figure 58: SWOT Analysis of Genzyme 95
Figure 59: Genzyme, Annual Revenue Forecasts, ($m), 2004-2012 97
Figure 60: Genzyme, Net Income and R&D Expense, ($m), 2004-2008 98
Figure 61: Genzyme, Earnings per Share, ($), 2004-2008 99
Figure 62: Genzyme, Net Profit Margin, (%), 2004-2008 100
Figure 63: Genzyme, Current Ratio, 2004-2008 101
Figure 64: Genzyme, Debt to Equity Ratio, 2004-2008 102
Figure 65: Genzyme, Return on Equity, (%), 2004-2008 103
Figure 66: DuPont Analysis for Genzyme, 2004-2008 103
Figure 67: Therapeutic Focus of Genzyme R&D Pipeline, 2009 104
Figure 68: R&D Productivity for Genzyme, 2004-2008 105
Figure 69: Phase-wise Analysis of Genzyme R&D Pipeline, 2009 106
Figure 70: SWOT Analysis of Biogen Idec 110
Figure 71: Biogen Idec, Annual Revenue Forecasts, ($m), 2004-2012 112
Figure 72: Biogen Idec, Net Income and R&D Expense, ($m), 2004-2008 113
Figure 73: Biogen Idec, Earnings per Share, ($), 2004-2008 114
Figure 74: Biogen Idec, Net Profit Margin, (%), 2004-2008 115
Figure 75: Biogen Idec, Current Ratio, 2004-2008 116
Figure 76: Biogen Idec, Debt to Equity Ratio, 2004-2008 117
Figure 77: Biogen Idec, Return on Equity, (%), 2004-2008 118
Figure 78: DuPont Analysis for Biogen Idec, 2004-2008 118
Figure 79: Therapeutic Focus of Biogen Idec R&D Pipeline, 2009 119
Figure 80: R&D Productivity for Biogen Idec, 2004-2008 120



Figure 81: Phase-wise Analysis of Biogen Idec R&D Pipeline, 2009 121
Figure 82: SWOT Analysis of CSL Limited 124
Figure 83: CSL Limited, Annual Revenue Forecasts, ($m), 2005-2013 126
Figure 84: CSL Limited, Net Income and R&D Expense, ($m), 2005-2009 127
Figure 85: CSL Limited, Earnings per Share, ($), 2005-2009 128
Figure 86: CSL Limited, Net Profit Margin, (%), 2005-2009 129
Figure 87: CSL Limited, Current Ratio, 2005-2009 130
Figure 88: CSL Limited, Debt to Equity Ratio, 2005-2009 131
Figure 89: CSL Limited, Return on Equity, (%), 2005-2009 132
Figure 90: DuPont Analysis for CSL Limited, 2005-2009 132
Figure 91: Therapeutic Focus of CSL Limited R&D Pipeline, 2009 133
Figure 92: R&D Productivity for CSL Limited, 2005-2009 134
Figure 93: Phase-wise Analysis of CSL Limited R&D Pipeline, 2009 135
Figure 94: SWOT Analysis of Celgene 138
Figure 95: Celgene, Annual Revenue Forecasts, ($m), 2004-2012 140
Figure 96: Celgene, Net Income and R&D Expense, ($m), 2004-2008 141
Figure 97: Celgene, Earnings per Share, ($), 2004-2008 142
Figure 98: Celgene, Net Profit Margin, (%), 2004-2008 142
Figure 99: Celgene, Current Ratio, 2004-2008 143
Figure 100: Celgene, Debt to Equity Ratio, 2004-2008 144
Figure 101: Celgene, Return on Equity, (%), 2004-2008 145
Figure 102: DuPont Analysis for Celgene, 2004-2008 145
Figure 103: Therapeutic Focus of Celgene R&D Pipeline, 2009 146
Figure 104: R&D Productivity for Celgene, 2004-2008 147
Figure 105: Phase-wise Analysis of Celgene R&D Pipeline, 2009 148
Figure 106: SWOT Analysis of Cephalon 151
Figure 107: Cephalon, Annual Revenue Forecasts, ($m), 2004-2012 153
Figure 108: Cephalon, Net Income and R&D Expense, ($m), 2004-2008 154
Figure 109: Cephalon, Earnings per Share, ($), 2004-2008 155
Figure 110: Cephalon, Net Profit Margin, (%), 2004-2008 155
Figure 111: Cephalon, Current Ratio, 2004-2008 156
Figure 112: Cephalon, Debt to Equity Ratio, 2004-2008 157
Figure 113: Cephalon, Return on Equity, (%), 2004-2008 158
Figure 114: DuPont Analysis for Cephalon, 2004-2008 158
Figure 115: Therapeutic Focus of Cephalon R&D Pipeline, 2009 159
Figure 116: R&D Productivity for Cephalon, 2004-2008 160
Figure 117: Phase-wise Analysis of Cephalon R&D Pipeline, 2009 161
Figure 118: SWOT Analysis of Actelion 164
Figure 119: Actelion, Annual Revenue Forecasts, ($m), 2004-2012 165
Figure 120: Actelion, Net Income and R&D Expense, ($m), 2004-2008 166
Figure 121: Actelion, Earnings per Share, ($), 2004-2008 167
Figure 122: Actelion, Net Profit Margin, (%), 2004-2008 168
Figure 123: Actelion, Current Ratio, 2004-2008 169
Figure 124: Actelion, Debt to Equity Ratio, 2004-2008 170
Figure 125: Actelion, Return on Equity, (%), 2004-2008 171
Figure 126: DuPont Analysis for Actelion, 2004-2008 171
Figure 127: Therapeutic Focus of Actelion R&D Pipeline, 2009 172
Figure 128: R&D Productivity for Actelion, 2004-2008 173
Figure 129: Phase-wise Analysis of Actelion R&D Pipeline, 2009 174
Figure 130: GBI Research Methodology 179



Companies Mentioned
Amgen
Genentech (Roche)
Gilead Sciences
UCB Pharma
Genzyme
Biogen Idec
CSL Limited
Celgene
Cephalon
Actelion



Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.

Top 10 Biotechnology Companies - SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline

Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 3 500.00 Quantity: _____

Site License--USD 7 000.00 Quantity: _____

Corporate License--USD 10 500.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________



Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Top 10 Biotechnology Companies - SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Mehr von ReportLinker.com

Mehr von ReportLinker.com (20)

Kürzlich hochgeladen

Kürzlich hochgeladen (20)

Top 10 Biotechnology Companies - SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline